The objective of study is to evaluate the efficacy and safety of 1 year duration of DAPT after GENOSS® DES Implantation in patients with coronary artery disease according to the complex higher-risk (and indicated) procedure.
Patients of 19 and over
Patients with coronary artery disease treated with GENOSS SES
Participants who voluntarily decide to participate in this clinical trial, agree to the study protocol and clinical follow-up plan, and provide written informed consent as study participants
Patients with cardiogenic shock at the time of hospitalization
Patients who are pregnant or planning to become pregnant
Patients with a life expectancy of less than 1 year
Patients participating in randomized controlled trials using other medical devices
Patients with coronary artery disease treated with GENOSS DES
Case-only
Prospective
Not listed
Device-oriented composite endpoint
DOCE is defined as a composite of cardiac death, target vessel-related myocardial infarction (TV-MI) and clinically indicated target-lesion revascularization (TLR).
Patient-oriented composite endpoint
POCE is defined as a composite of all-cause death, any myocardial infarction, and any revascularization.
All-cause deaths
Cardiac death
Non-cardiac death
Click on the lead sponsor to view all of their trials.
